Literature DB >> 26622749

Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Junichi Soh1, Shinichi Toyooka2, Keitaro Matsuo3, Hiromasa Yamamoto4, Ignacio I Wistuba5, Stephen Lam6, Kwun M Fong7, Adi F Gazdar8, Shinichiro Miyoshi4.   

Abstract

Mutations or copy number gains (CNGs) of the EGFR and KRAS genes are representative alterations in lung adenocarcinomas that are individually associated with patient characteristics such as ethnicity, smoking status and gender. However, the effects of combinations of these genetic alterations have not been statistically examined. The present study analyzed previously examined lung adenocarcinoma cases in Asian (n=166) and non-Asian (n=136) individuals in whom all four EGFR and KRAS alterations had been studied. The polynomial logistic regression models were used following adjustment for gender and smoking status, and using patients without any type of EGFR/KRAS alterations as a reference. Between the two ethnic groups, EGFR CNGs (gEGFR) occurred more frequently than EGFR mutations (mEGFR) (46 vs. 38% in Asians; 21 vs. 10% in non-Asians), whereas KRAS mutations (mKRAS) were more frequent than KRAS CNGs (gKRAS) (13 vs. 7% and 35 vs. 4%, respectively). Additionally, gEGFR and gKRAS occurred significantly more frequently in respective mutant cases, and all EGFR alterations were almost exclusive of all KRAS alterations. The polynomial logistic regression models confirmed that all types of EGFR alterations were significantly more frequent among Asian individuals than among non-Asian individuals, independent of gender and smoking status (odds ratios, 2.36-6.67). KRAS alterations occurred less frequently among Asian individuals than among non-Asian individuals, although a significant difference was not detected. The present study results indicated that the EGFR and KRAS profiles, including mutations and CNGs, differ between Asian and non-Asian individuals with lung adenocarcinoma, suggesting that ethnicity strongly affects the molecular characteristics of lung adenocarcinoma.

Entities:  

Keywords:  EGFR; KRAS; copy number gain; ethnicity; lung adenocarcinoma; mutation

Year:  2015        PMID: 26622749      PMCID: PMC4533243          DOI: 10.3892/ol.2015.3414

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Missense mutations of the BRAF gene in human lung adenocarcinoma.

Authors:  Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.

Authors:  Patrick L Wagner; Sven Perner; David S Rickman; Christopher J LaFargue; Naoki Kitabayashi; Stephen F Johnstone; Barbara A Weir; Matthew Meyerson; Nasser K Altorki; Mark A Rubin
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493

3.  The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.

Authors:  Shuji Ichihara; Shinichi Toyooka; Yoshiro Fujiwara; Katsuyuki Hotta; Hisayuki Shigematsu; Masaki Tokumo; Junichi Soh; Hiroaki Asano; Kouichi Ichimura; Keisuke Aoe; Motoi Aoe; Katsuyuki Kiura; Kenji Shimizu; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Int J Cancer       Date:  2007-03-15       Impact factor: 7.396

4.  Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.

Authors:  Cheryl Ho; Nevin Murray; Janessa Laskin; Barbara Melosky; Helen Anderson; Gwyn Bebb
Journal:  Lung Cancer       Date:  2005-08       Impact factor: 5.705

Review 5.  Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Issa J Dahabreh; Helena Linardou; Fotios Siannis; Paris Kosmidis; Dimitrios Bafaloukos; Samuel Murray
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

6.  Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Authors:  Anne S Tsao; Xi Ming Tang; Bradley Sabloff; Lianchun Xiao; Hisayuki Shigematsu; Jack Roth; Margaret Spitz; Waun Ki Hong; Adi Gazdar; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2006-03       Impact factor: 15.609

7.  Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.

Authors:  Hidefumi Sasaki; Yu Hikosaka; Osamu Kawano; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

8.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

9.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

Authors:  Rom S Leidner; Pingfu Fu; Bradley Clifford; Ayad Hamdan; Cheng Jin; Rosana Eisenberg; Titus J Boggon; Margaret Skokan; Wilbur A Franklin; Federico Cappuzzo; Fred R Hirsch; Marileila Varella-Garcia; Balazs Halmos
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

10.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

View more
  13 in total

Review 1.  Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review.

Authors:  Jasmina Obradovic; Jovana Todosijevic; Vladimir Jurisic
Journal:  Mol Biol Rep       Date:  2021-05-10       Impact factor: 2.316

2.  Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.

Authors:  Nicholas T Gimbrone; Bhaswati Sarcar; Edna R Gordian; Jason I Rivera; Christian Lopez; Sean J Yoder; Jamie K Teer; Eric A Welsh; Alberto A Chiappori; Matthew B Schabath; Gary W Reuther; Julie Dutil; Miosotis Garcia; Ronald Ventosilla-Villanueva; Luis Vera-Valdivia; Alejandro Yabar-Berrocal; Rodrigo Motta-Guerrero; Pedro G Santiago-Cardona; Teresita Muñoz-Antonia; W Douglas Cress
Journal:  J Thorac Oncol       Date:  2017-09-11       Impact factor: 15.609

3.  Presentation of EGFR mutations in 162 family probands with multiple primary lung cancer.

Authors:  Chunxiang Li; Yalong Wang; Kai Su; Yu Liu; Liyu Wang; Bo Zheng; Na Yan; Dawei Yuan; Yanxiang Zhang; Liyan Xue; Shugeng Gao; Jie He
Journal:  Transl Lung Cancer Res       Date:  2021-04

4.  Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status.

Authors:  Hongwei Li; Weili Wang; Haixia Jia; Jianhong Lian; Jianzhong Cao; Xiaqin Zhang; Xing Song; Sufang Jia; Zhengran Li; Xing Cao; Wei Zhou; Songye Han; Weihua Yang; Yanfen Xi; Shenming Lian
Journal:  Thorac Cancer       Date:  2017-06-09       Impact factor: 3.500

5.  The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.

Authors:  Engeng Chen; Zhiru Zeng; Bingjun Bai; Jing Zhu; Zhangfa Song
Journal:  Oncotarget       Date:  2016-08-30

Review 6.  Lung cancer in women in 21th century.

Authors:  Joanna Domagala-Kulawik; Anna Trojnar
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

Review 7.  Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation.

Authors:  Vladimir Jurišić; Jasmina Obradovic; Sonja Pavlović; Nataša Djordjevic
Journal:  Anal Cell Pathol (Amst)       Date:  2018-10-14       Impact factor: 2.916

8.  Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.

Authors:  Yuki Nukii; Atsushi Miyamoto; Sayaka Mochizuki; Shuhei Moriguchi; Yui Takahashi; Kazumasa Ogawa; Kyoko Murase; Shigeo Hanada; Hironori Uruga; Hisashi Takaya; Nasa Morokawa; Kazuma Kishi
Journal:  BMC Cancer       Date:  2019-02-28       Impact factor: 4.430

Review 9.  The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).

Authors:  Ravi Salgia; Rebecca Pharaon; Isa Mambetsariev; Arin Nam; Martin Sattler
Journal:  Cell Rep Med       Date:  2021-01-19

10.  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma.

Authors:  David J H Shih; Naema Nayyar; Ivanna Bihun; Ibiayi Dagogo-Jack; Corey M Gill; Elisa Aquilanti; Mia Bertalan; Alexander Kaplan; Megan R D'Andrea; Ugonma Chukwueke; Franziska Maria Ippen; Christopher Alvarez-Breckenridge; Nicholas D Camarda; Matthew Lastrapes; Devin McCabe; Ben Kuter; Benjamin Kaufman; Matthew R Strickland; Juan Carlos Martinez-Gutierrez; Deepika Nagabhushan; Magali De Sauvage; Michael D White; Brandyn A Castro; Kaitlin Hoang; Andrew Kaneb; Emily D Batchelor; Sun Ha Paek; Sun Hye Park; Maria Martinez-Lage; Anna S Berghoff; Parker Merrill; Elizabeth R Gerstner; Tracy T Batchelor; Matthew P Frosch; Ryan P Frazier; Darrell R Borger; A John Iafrate; Bruce E Johnson; Sandro Santagata; Matthias Preusser; Daniel P Cahill; Scott L Carter; Priscilla K Brastianos
Journal:  Nat Genet       Date:  2020-03-23       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.